CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 3 | 750 | Europe, Canada, Japan, US, RoW | Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine | Stichting European Myeloma Network, Janssen Research & Development, LLC | Multiple Myeloma | 06/33 | 08/40 | | |
NCT03751917: Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia |
|
|
| Recruiting | N/A | 100 | Europe | Arsenic Trioxide, ATRA+ATO | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Promyelocytic Leukemia | 12/24 | 12/24 | | |
